
© 2024 Edison Investment Research
Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,750 | 2,760 | 16:39 | |
2,740 | 2,765 | 16:40 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mo | Oryzon Genomics, S.A.: ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat | MADRID and CAMBRIDGE, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics... ► Artikel lesen | |
15.04. | Oryzon Genomics - First patient dosed in iadademstat + ICI SCLC trial | Oryzon Genomics has announced that the first patient has been dosed in iadademstat's Phase I/II trial, sponsored by the National Cancer Institute, (NCI) in extensive-stage small cell lung cancer (SCLC).... ► Artikel lesen | |
14.03. | Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in March-April | BIO-Europe Spring 2025Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage... ► Artikel lesen | |
05.03. | Oryzon Genomics, S.A.: Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat | ||
05.03. | Oryzon (BME: ORY) publishes results of vafidemstat in PMS | Oryzon Genomics has announced the publication of a study in Frontiers in Psychiatry, which explores the potential of vafidemstat in Phelan-McDermid Syndrome (PMS). PMS is a form of autism whereby agitation... ► Artikel lesen |